Chronic disease
Managing Long-Term Competition in Established Markets
Sustainable Advantage in Chronic Disease Markets
Chronic disease markets — spanning cardiometabolic conditions, respiratory diseases, CNS disorders, and autoimmune indications — are among the largest and most contested in pharma. Established treatment algorithms, entrenched prescriber habits, biosimilar and generic erosion, and the rising influence of real-world evidence on payer decisions make competitive positioning extraordinarily nuanced.
Our chronic disease competitive intelligence helps you understand how treatment guidelines are evolving, where biosimilar and generic penetration is accelerating, how competitors are using real-world evidence to support their value stories, and what value-based contracting arrangements are reshaping payer relationships. We give you the strategic clarity to defend your position, launch lifecycle extensions, or identify adjacencies for growth.
What We Analyse
What You Will Receive
Competitive Dynamics Report
Positioning of top-5 competitors across clinical, commercial, access, and medical affairs dimensions.
Biosimilar & Generic Threat Model
Entry timelines, expected erosion curves, and commercial response playbook options.
RWE Strategy Benchmark
How competitors are generating and deploying real-world data to support formulary position and prescriber preference.
Lifecycle Management Options
Mapped opportunities for new indications, formulations, combination approaches, and companion services.
Who This Intelligence Is For
- Commercial and market access teams in established pharma brands
- Medical affairs and HEOR functions supporting product lifecycle
- Portfolio and business development strategy teams
- Healthcare investors evaluating specialty pharma or biosimilar assets
Ready to gain an edge?
Connect with our team to discuss how our Chronic disease intelligence can support your strategic objectives.
Schedule a Consultation